title: Caveolin-1 regulates the secretion and cytoprotection of Cyr61 in hyperoxic cell death.
abstract: Cysteine-rich 61 (Cyr61) belongs to the CCN family and mediates cell proliferation, survival, and apoptosis. Our previous studies showed that Cyr61 protected against hyperoxia-induced lung cell death via Akt phosphorylation. Caveolin-1 (cav-1), a 22-kDa transmembrane scaffolding protein, is the principal structural component of caveolae. Emerging data show that cav-1 regulates signal transduction-associated proteins that reside in the caveolae. Numerous integrin-related pathways, including PI3K/Akt-induced cell survival are controlled by cav-1-mediated signaling. Our data showed that recombinant Cyr61 promoted cell proliferation and resistance to hyperoxia-induced cell death in vitro. Neutralizing antibodies reversed the above effects, indicating functional role of secreted Cyr61 in response to hyperoxic stress. While deletion of cav-1 protected cells from hyperoxia-induced cell death, Cyr61-neutralizing antibodies abolished this protective effect. Furthermore, Cyr61 and cav-1 colocalized and physically interacted via integrins in bronchial epithelial cells. Deletion of cav-1 increased extracellular and decreased cytosolic Cyr61, both in vitro and in vivo. Pretreatment with Brefeldin A increased intracellular Cyr61 in cav-1(-/-) cells, while decreasing extracellular Cyr61. Taken together, Cav-1/Cyr61 interaction via integrins represents a novel pathway of Cyr61 signaling involving cav-1-dependent processes, which play a critical role in regulating hyperoxia-induced cell death.
authors.affiliation: Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
authors.forename: Yang
authors.initials: Y
authors.lastname: Jin
authors.forename: Hong Pyo
authors.initials: HP
authors.lastname: Kim
authors.forename: Jiaofei
authors.initials: J
authors.lastname: Cao
authors.forename: Meng
authors.initials: M
authors.lastname: Zhang
authors.forename: Emeka
authors.initials: E
authors.lastname: Ifedigbo
authors.forename: Augustine M K
authors.initials: AM
authors.lastname: Choi
mesh_terms: D000818:Animals; D000906:Antibodies / Q000276:immunology / Q000494:pharmacology; D051242:Caveolin 1 / Q000172:deficiency / Q000235:genetics / Q000378:metabolism* / Q000494:pharmacology*; D016923:Cell Death / Q000187:drug effects; D015687:Cell Hypoxia / Q000187:drug effects; D049109:Cell Proliferation; D002478:Cells, Cultured; D055515:Cysteine-Rich Protein 61 / Q000276:immunology / Q000378:metabolism*; D019610:Cytoprotection / Q000187:drug effects*; D005089:Exocytosis; D005786:Gene Expression Regulation; D039564:Integrin alphaV / Q000378:metabolism; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D011485:Protein Binding
chemical_list: D000906:Antibodies; D051242:Caveolin 1; D055515:Cysteine-Rich Protein 61; D039564:Integrin alphaV
references.citation: Cell. 1998 Sep 4;94(5):625-34
references.pmid: 9741627
references.citation: Biochem Biophys Res Commun. 2007 Apr 13;355(3):611-8
references.pmid: 17316559
references.citation: J Biol Chem. 1998 Mar 6;273(10):5419-22
references.pmid: 9488658
references.citation: Mol Pathol. 2001 Apr;54(2):57-79
references.pmid: 11322167
references.citation: Proc Natl Acad Sci U S A. 2004 Oct 12;101(41):14895-900
references.pmid: 15469929
references.citation: J Biol Chem. 1998 Jan 30;273(5):3090-6
references.pmid: 9446626
references.citation: FASEB J. 2008 Mar;22(3):828-40
references.pmid: 17905724
references.citation: J Exp Med. 2006 Dec 25;203(13):2895-906
references.pmid: 17178917
references.citation: Bone. 2000 Jul;27(1):53-60
references.pmid: 10865209
references.citation: Cell Cycle. 2006 Oct;5(19):2179-82
references.pmid: 16969102
references.citation: J Cell Biol. 1999 Mar 22;144(6):1285-94
references.pmid: 10087270
references.citation: Biochem Biophys Res Commun. 2005 Dec 23;338(3):1383-90
references.pmid: 16263077
references.citation: J Virol. 2004 Dec;78(24):13479-88
references.pmid: 15564459
references.citation: Proc Natl Acad Sci U S A. 1998 May 26;95(11):6355-60
references.pmid: 9600969
references.citation: J Cell Mol Med. 2007 Sep-Oct;11(5):969-80
references.pmid: 17979878
references.citation: Endocrinology. 2001 Jun;142(6):2540-8
references.pmid: 11356703
references.citation: Mol Cancer Res. 2007 Nov;5(11):1111-23
references.pmid: 18025257
references.citation: Mol Membr Biol. 1995 Jan-Mar;12(1):121-4
references.pmid: 7767370
references.citation: Am J Physiol. 1998 Nov;275(5 Pt 1):L843-51
references.pmid: 9815100
references.citation: Endocr Relat Cancer. 2003 Jun;10(2):141-52
references.pmid: 12790776
references.citation: Cancer Cell Int. 2003 Aug 22;3(1):15
references.pmid: 12969515
references.citation: Oncogene. 2005 Jan 27;24(5):761-79
references.pmid: 15592521
references.citation: Curr Pharm Des. 2004;10(31):3913-28
references.pmid: 15579080
references.citation: Exp Cell Res. 1997 May 25;233(1):63-77
references.pmid: 9184077
references.citation: Oncogene. 1998 Feb 12;16(6):747-54
references.pmid: 9488038
references.citation: J Biol Chem. 2002 Nov 29;277(48):46248-55
references.pmid: 12364323
references.citation: J Biol Chem. 1998 Oct 9;273(41):26962-8
references.pmid: 9756945
references.citation: Protein Expr Purif. 2005 Jul;42(1):219-25
references.pmid: 15878827
references.citation: Am J Respir Cell Mol Biol. 2005 Sep;33(3):297-302
references.pmid: 15961723
references.citation: J Cell Sci. 2006 Dec 1;119(Pt 23):4803-10
references.pmid: 17130294
references.citation: Nat Cell Biol. 2005 Sep;7(9):901-8
references.pmid: 16113676
references.citation: Trends Cell Biol. 2007 May;17(5):246-50
references.pmid: 17363257
references.citation: Cell. 1996 Nov 15;87(4):733-43
references.pmid: 8929541
references.citation: J Endocrinol. 2003 Aug;178(2):169-75
references.pmid: 12904165
references.citation: Exp Cell Res. 1999 Apr 10;248(1):44-57
references.pmid: 10094812
references.citation: J Biol Chem. 1995 Mar 24;270(12):6838-42
references.pmid: 7896831